Here are the 10-K annual reports from Assembly Biosciences, Inc (ASMB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ASMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASMB filings page.
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on next-generation antiviral drugs for serious viral diseases, including recurrent genital herpes, hepatitis B and D, and transplant-associated herpesviruses. Its pipeline features two long-acting helicase-primase inhibitors (5366 and 1179), an oral HDV entry inhibitor (6250), a next-generation HBV capsid assembly modulator (4334) and a broad-spectrum NNPI (7272).
In 2025 the company reported multiple positive Phase 1 data readouts across 5366, 1179, 4334 and 6250, generally showing strong antiviral activity, pharmacokinetics supporting convenient oral dosing and favorable safety profiles. Gilead Sciences exercised its option in December 2025 to exclusively license the HPI program, paying $35 million and taking over global development and commercialization, while Assembly remains eligible for up to $330 million in milestones plus tiered royalties and may later elect a 40% U.S. profit-share.
Assembly retains full control of 4334 after Gilead declined its option in March 2026 and is seeking a partner before advancing that HBV program. For HDV, Phase 2 initiation of 6250 is targeted for the fourth quarter of 2026. As of March 13, 2026, Assembly had 15,862,705 shares of common stock outstanding, and the aggregate market value of non-affiliate voting stock was $97.8 million as of June 30, 2025.